172 results about "Skin penetration enhancer" patented technology

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting hormone to an animal which comprises applying an effective amount of the hormone in the form of the drug delivery system of the present invention

Anti-infective foamable composition and kits include a foamable carrier; a therapeutically safe and effective concentration of an anti-infective agent; an augmenting agent selected from the group consisting of a keratolytic agent and a skin penetration enhancer; and a propellant. The composition is housed in a container and upon release is expandable to form a breakable foam. The foamable carrier is selected to generate a foam of good or excellent quality in the presence of the augmenting agent and anti-infective agent. Methods for treating, alleviating or preventing a disorder of the skin, a body cavity or mucosal surface, wherein the disorder involves a fungal, bacterial or viral infection as one of its etiological factors, is described.

The present invention relates to a delivery system which includes a bioactive drug or cosmetic substance presented in the form of submicron oil spheres alone, or drugs or cosmetic substances in a combination with the oil spheres in an aqueous suspension or emulsion. Optionally, a skin penetration enhancer may be included in such formulations. Such preparations achieve improved bioavailability and exert larger pharmacological effects than an equivalent dose of the drug or cosmetic formulated in conventional creams, lotions or oleaginous bases.

An alcohol-free, transdermal drug delivery composition administered via a metered spray drug delivery device is described herein. The non-occlusive transdermal drug delivery composition includes a therapeutically effective amount of at least one physiologically active agent or prodrug thereof, an effective amount of at least one dermal penetration enhancer; and at least one non-volatile liquid. The transdermal drug delivery composition is administered to a dermal or mucosal surface of an animal needing the same using a metered spray device capable of delivering a fine spray of substantially uniform particle size to minimize the required drying time therefor.

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an analgesic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting analgesic to an animal which comprises applying an effective amount of the analgesic in the form of the drug delivery system of the present invention.

A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent;

and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (C_max) to the average concentration (C_avg) for the physiologically active agent over the dosage interval within the range of 1 to 10.

The invention provides a sterile polymerized covering for a wound surface-medical wet dressing for a burn wound, a preparation method of the dressing, and application. The dressing comprises the following components: 10 to 30g of chitosan, 30 to 80g of polyving akohol, 5 to 10g of alginate, 5 to 15g of isomaltose hypgather, 2 to 6g of carbomer 940, 2 to 5g of gelatin, 5 to 10g of sodium carboxymethylcellulose, 10 to 30g of glycerol, and 0.01 to 0.2g of menthol; 15 to 60g of condensed tannin which is remarkable in treatment can be selectively added; and a skin penetration enhancer or an appearance conditioning agent also can be selectively added. The dressing can be prepared into an irregular dressing in order to be suitable for the wound surfaces in irregular and special positions and also can be prepared into a solid plate-shaped dressing which can be shorn at random. According to the sterile polymerized covering dressing for the wound surface, the freezing and thawing technology and the irradiating technology are combined and cross-linked to realize the preparation, and the defects of the prior art can be overcome. The dressing is high in biocompatibility, free from toxicity and sensitization and high in mechanical strength and comfort level, is out of adhering during the process of being replaced after being attached for a long time, and is a nonantigenic protective barrier which has the effect of resisting and inhibiting bacteria.

The topical medicament gel formulation of the present invention includes an anesthetic, an anti-microbial, an oxidant, a nutrient, a diuretic, an opioid, an anti-emetic, an anti-seizure drug, and a non-steroidal anti-inflammatory drug (NSAID), USP in a molecular, as opposed to a salt form, as the active ingredient. Additional constituents illustratively include a skin penetration enhancer and a gelling agent. This invention deals with problems commonly associated with topical application of local medicaments such as: slow onset of action; need for occlusion; and rapid loss of effect due to rapid systemic dispersion. The invention permits enhanced penetration of the medicament and thereby allows for a lesser total dosage of pharmaceutically active ingredient. The use of a lesser total dosage also decreases systemic toxicity.

The invention provides a red sage root mask. The red sage root mask is prepared by adding a mask matrix and water into total salvianolic acid utilized as an active ingredient, wherein, the matrix comprises the following components in parts by weight: 4.9-14.7 parts of the total salvianolic acid, 22.4-67.2 parts of a film-forming material, 7.8-23.4 parts of a thickening agent, 4.9-14.7 parts of a skin penetration enhancer, 0.25-0.75 parts of an antioxidant and 1-3 parts of a preservative. The invention further provides a preparation method of the red sage root mask. The red sage root mask is a peel-off mask, wherein, the total salvianolic acid has an effect on promoting body surface microcirculation, thus smoothening the body surface blood circulation, accelerating the blood flow velocity, fully moisturizing and nourishing skin and hair and ensuring the stability of water-soluble components of red sage root. Therefore, the red sage root mask can be widely used in health and skin care.

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiemetic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiemetic thereof to an animal which comprises applying an effective amount of the antiemetic in the form of the drug delivery system of the present invention.

Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous compositions that include the compound together with a bulking agent that can be a non-aqueous liquid or a solid in a sheet, film or powder form. The composition can optionally include a skin penetration enhancer. A non-aqueous, solid dosage form comprises a PGE compound substantially uniformly distributed in a carrier sheet or film.

The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antianxiety agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antianxiety agent to an animal which comprises applying an effective amount of the antianxiety agent in the form of the drug delivery system of the present invention.

The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that skin to energy of a wavelength capable of activating the photosensitizer.

The invention relates to a formula and a preparing method of a freeze-dried excipient preparation. The formula is new and simplified. By controlling the ratio of an adhesive and the ratio of active components in the freeze-dried excipient preparation, the freeze-dried excipient preparation can be free of a skeleton supporting agent system and only contains the adhesive and the active components. The skeleton supporting agent comprises, but not limited to, sugar, sugar alcohol, amino acids having 2-12 carbon atoms, inorganic salts, and the like. Based on this, an antioxidant, a corrigent, essence, a skin penetration enhancer, a pH modifier, and other auxiliary materials can be added into the preparation. By avoiding the use of the skeleton supporting agent, technical effects of reducing the moisture adsorption risk, simplifying the preparing process, reducing the cost and increasing the drug loading capacity per unit are achieved.

The invention relates to an anti-parasitic ivermectin transdermal solution used for livestock and a preparation method thereof. The anti-parasitic ivermectin transdermal solution comprises the following components respectively according to parts by volume: 5 to 15 parts of ethyl acetate, 20 to 30 parts of dimethyl sulfoxide, 2 to 6 parts of azone, 1 to 3 parts of isopropanol and 50 to 70 parts of propanediol; and the content of ivermectin is 0.3g to 1g in a solution of 100ml, and the finished product is prepared by the processes of dissolving, mixing, filtering and filling. The azone related in the prescription of the invention is a novel skin penetration enhancer, can increase the transdermal absorption of the skin to various medicines of different types, effectively avoids the pass effect of hepar, avoids peak and valley phenomena in the absorption process of the medicine, reduces the toxic or side effect caused by the correlative dosage in the medicine, prolongs the effective effect time, changes the administration area, effectively regulates the administration dosage and reduces differences among individuals. The invention has the characteristic of simple, convenient and fast use, and is more suitable for the anti-parasitic prevention and treatment of a pasturing area compared with other preparation forms.

This invention pertains to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drugs (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, minor strains, pains, and contusions. This invention particularly relates to transdermal compositions comprising an NSAID, a bioadhesive graft copolymer, and a skin penetration enhancer, selected from pyrrolidone or its derivatives and dialkyl sulfoxides and combinations thereof.

A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Topically applied formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well.

The invention relates to a hydrogel mask with a whitening effect and a preparation method thereof and belongs to the technical field of masks. The hydrogel mask contains a support layer and a gel layer. The gel layer contains the following ingredients (by weight): a cellulose derivative water-soluble polymer, an enzymatic bearberry leaf extract, a lemon extract, arginine, lavender essential oil, chamomile essential oil, an aloe extract, tartaric acid, a skin penetration enhancer, sodium chloride, vitamin E, carbomer, glycerin, essence, a preservative and water. By the use of natural medicinal materials and through enzymolysis of bearberry leaf, active materials are decomposed into micromolecules. Thus, effects are enhanced. The hydrogel mask has advantages of good whitening effect and skin maintenance.